Serving To Educate Primary Care Clinicians On Metabolic Issues
Evidence Based Medicine Header 1
Medical Education Header 2
Peer-to-peer Exchange Header 3
Metabolic Diseases Header 4
News: Consultant 360 Metabolic Disease Articles April 2020

New Metabolic Disease Articles from our Partners at Consultant 360

Which Antidiabetic Drugs Are Associated With Improved Left Ventricular Function?

In a recent systematic review and meta-analysis, researchers compared the effects of SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 agonists, and other antidiabetic agents in improving left ventricular remodeling among patients with type 2 diabetes and CVD.

https://www.consultant360.com/exclusive/endocrinology/diabetes/which-antidiabetic-drugs-are-associated-improved-left-ventricular

In ACS, White Blood Cell Count Affects the Risk of Ischemic Events

Researchers investigated the association between white blood cell count with bleeding and ischemic events in patients with acute coronary syndrome.

https://www.consultant360.com/exclusive/cardiology/acs-white-blood-cell-count-affects-risk-ischemic-events 

Low vs Preserved SBP Following Cardiac Resynchronization Therapy

The researchers hypothesized that assessing systolic blood pressure 1 year after cardiac resynchronization therapy can help identify patients with increased risk of adverse cardiovascular outcomes.

https://www.consultant360.com/exclusive/cardiology/low-vs-preserved-sbp-following-cardiac-resynchronization-therapy 

Is LDL-C–Lowering Therapy Less Effective for Patients With a Higher BMI?

It is uncertain how body mass index impacts cardiovascular outcomes among patients receiving intensive low-density lipoprotein cholesterol–lowering therapy. New research has shed light on the association. 

https://www.consultant360.com/exclusive/cardiology/lipid-metabolic/ldl-c-lowering-therapy-less-effective-patients-higher-bmi 

SGLT2 Inhibitor Improves HbA1c and More in T2D and Overweight, Obesity

In an analysis of 3 placebo-controlled, randomized, Phase 3 studies of a selective SGLT2 inhibitor, researchers observed clinically meaningful decreases in glycated HbA1c, fasting plasma glucose, and more compared with placebo.

https://www.consultant360.com/exclusive/endocrinology/diabetes/sglt2-inhibitor-improves-hba1c-and-more-t2d-and-overweight-obesity